Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

GSK’s diabetes candidate enters phase III

February 19, 2009 Research and Development GSK, diabetes

A large scale study of GlaxoSmithKline's type II diabetes candidate Syncria (albiglutide) has begun.Albiglutide is an investigational biological drug, and …
News

Genzyme says new plant approval is imminent

February 18, 2009 Research and Development, Sales and Marketing Genzyme

Genzyme has said it expects to get approval to make a Pompe disease treatment at a new US manufacturing unit …
News

Lilly to boost biotech stake in NeuroSearch deal

February 17, 2009 Research and Development Denmark, Europe, NeuroSearch

Lilly has signed a new deal with Danish biotech company NeuroSearch and increased its presence further in the biologics sector.The …
News

Pharma needs fresh ideas from outside industry, says Barker

February 17, 2009 Research and Development, Sales and Marketing ABPI, strategy

Pharma must re-invent itself and inject new ideas into its business model by hiring talented people from outside the sector, …
News

GSK: renewing the HIV pipeline

February 16, 2009 Research and Development GSK, HIV

GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK …
News

Bayer’s cardiovascular drug enters phase III

February 13, 2009 Research and Development, Sales and Marketing Bayer, cv

Bayer Schering Pharma has begun phase III trials of riociguat for treatment of two life-threatening conditions. Two trials will investigate …
News

Publish and be damned?

February 10, 2009 Research and Development clinical trials, publication

Feature

Schering-Plough invests in Scotland drug discovery centre

February 6, 2009 Research and Development Merck, Scotland

Schering-Plough is to invest around $30 million in its early drug discovery work in Scotland. The company is investing a …
News

What are pharma’s core competencies?

February 5, 2009 Research and Development, Sales and Marketing pharma, strategy

Pharma has always been a highly profitable industry, and has historically been among the best performing industrial sectors in terms …
Feature

The Pharmafocus Interview: David Gillen

February 3, 2009 Research and Development Pfizer, UK, medicines access

David Gillen says he is a born optimist. But Pfizer UK’s medical director says this positive outlook doesn’t blind him …
Feature

Evidence HRT could reduce bowel cancer risk

February 2, 2009 Research and Development, Sales and Marketing HRT

A new study has found more evidence that hormone replacement therapy (HRT) may reduce a woman's risk of bowel cancer. …
News

The Pfizer-Wyeth merger

February 2, 2009 Research and Development, Sales and Marketing Pfizer, Wyeth, merger, sales

Before the merger, Pfizer faced a significant contraction in sales. Datamonitor's analysis suggests that the company's sales were declining at …
Feature

Working Life: Sam Knivett

January 23, 2009 Business Services, Research and Development Pfizer, UK, WL, Working Life, careers, compliance, drug safety

How did you find your way into your current role?From the age of 11 I wanted to be a farmer. …
Feature

Merck Serono’s multiple sclerosis drug on track for filing

January 23, 2009 Research and Development, Sales and Marketing MS, Merck Serono

Cladribine, a new oral treatment for multiple sclerosis is on track for a mid-2009 filing after the release of encouraging …
News

FDA finalises transgenic animals guide

January 23, 2009 Research and Development, Sales and Marketing FDA, US, reg

The route map for companies wishing to sell medicines made in genetically-engineered animals has been drawn up by the FDA. …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026